DRAFT landscape of COVID-19 candidate vaccines – 10 December 2020
52 candidate vaccines in clinical evaluation
COVID-19 Vaccine developer/manufacturer | Vaccine platform | Type of candidate vaccine | Number of doses | Timing of doses |
Route of Adminis- tration |
Clinical Stage | |||
Phase 1 | Phase 1/2 | Phase 2 | Phase 3 | ||||||
Sinovac | Inactivated | Inactivated | 2 | 0,14 days | IM |
NCT04383574 NCT04352608 Study Report NCT04551547 |
NCT04456595 669/UN6.KEP/EC/2020 NCT04582344 NCT04617483 |
||
Wuhan Institute of Biological Products/Sinopharm | Inactivated | Inactivated | 2 | 0,21 days | IM |
ChiCTR2000031809 Interim Report |
ChiCTR2000034780 ChiCTR2000039000 NCT04612972 |
||
Beijing Institute of Biological Products/Sinopharm | Inactivated | Inactivated | 2 | 0,21 days | IM |
ChiCTR2000032459 Study Report |
ChiCTR2000034780 NCT04560881 |
||
Bharat Biotech | Inactivated | Whole-Virion Inactivated | 2 | 0, 28 days | IM |
CTRI/2020/07/026300 CTRI/2020/09/027674 |
CTRI/2020/11/028976 NCT04641481 |
||
University of Oxford/AstraZeneca | Non-Replicating Viral Vector | ChAdOx1-S | 2 | 0,28 days | IM |
PACTR202006922165132 2020-001072-15 NCT04568031 Interim Report |
2020-001228-32 Study Report |
ISRCTN89951424 NCT04516746 NCT04540393 CTRI/2020/08/027170 |
|
CanSino Biological Inc./Beijing Institute of Biotechnology | Non-Replicating Viral Vector | Adenovirus Type 5 Vector | 1 | IM | ChiCTR2000030906 NCT04568811 Study Report |
ChiCTR2000031781 NCT04566770 Study Report |
NCT04526990 NCT04540419 |
||
Gamaleya Research Institute | Non-Replicating Viral Vector | Adeno-based (rAd26-S+rAd5-S) | 2 | 0,21 days | IM | NCT04436471 NCT04437875 Study Report |
NCT04587219 NCT04640233 |
NCT04530396 NCT04564716 NCT04642339 |
|
Janssen Pharmaceutical Companies | Non-Replicating Viral Vector | Adenovirus Type 26 vector | 1 2 | 0 0, 56 days | IM | NCT04436276 NCT04509947 |
NCT04535453 |
NCT04505722 ISRCTN14722499 |
|
Novavax | Protein Subunit | Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M | 2 | 0,21 days | IM | NCT04368988 Study Report |
NCT04533399 (phase 2b) |
2020-004123-16 NCT04611802 |
|
Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences | Protein Subunit | Adjuvanted recombinant protein (RBD-Dimer) expressed in CHO cells | 3 | 0, 28, 56 days | IM | NCT04445194 NCT04636333 |
NCT04550351 |
NCT04466085 |
ChiCTR2000040153 |
Moderna/NIAID | RNA | LNP-encapsulated mRNA | 2 | 0,28 days | IM | NCT04283461 Interim Report Final Report |
NCT04405076 |
NCT04470427 |
|
BioNTech/Fosun Pharma/Pfizer | RNA | 3 LNP-mRNAs | 2 | 0,21 days | IM | NCT04368728 Study Report |
2020-001038-36 ChiCTR2000034825 NCT04537949 NCT04588480 Study Report1 Study Report2 |
NCT04368728 |
|
Medicago Inc. | VLP | Plant-derived VLP adjuvanted with AS03. | 2 | 0, 21 days | IM | NCT04450004 |
NCT04636697 |
||
Inovio Pharmaceuticals/ International Vaccine Institute | DNA | DNA plasmid vaccine with electroporation | 2 | 0, 28 days | ID | NCT04447781 NCT04336410 |
NCT04642638 ChiCTR2000040146 |
||
Beijing Wantai Biological Pharmacy/ Xiamen University | Replicating Viral Vector | Intranasal flu-based-RBD | 1 | IN | |||||
West China Hospital, Sichuan University | Protein Subunit | RBD (baculovirus production expressed in Sf9 cells) | 2 or 3 | 0, 28 days and 0,14, 28 days | IM | ChiCTR2000039994 |
|||
Curevac | RNA | mRNA | 2 | 0, 28 days | IM | NCT04449276 |
NCT04515147 |
||
Institute of Medical Biology, Chinese Academy of Medical Sciences | Inactivated | Inactivated | 2 | 0, 28 days | IM | NCT04412538 |
NCT04470609 |
||
Research Institute for Biological Safety Problems, Rep of Kazakhstan | Inactivated | Inactivated | 2 | 0, 21 days | IM | NCT04530357 |
|||
Shenzhen Kangtai Biological Products Co., Ltd. | Inactivated | Inactivated | 2 | IM | ChiCTR2000038804 |
ChiCTR2000039462 |
|||
Osaka University/ AnGes/ Takara Bio | DNA | DNA plasmid vaccine + Adjuvant | 2 | 0, 14 days | IM | NCT04463472 NCT04527081 |
|||
Cadila Healthcare Limited | DNA | DNA plasmid vaccine | 3 | 0, 28, 56 days | ID | CTRI/2020/07/026352 |
|||
Genexine Consortium | DNA | DNA Vaccine (GX-19) | 2 | 0, 28 days | IM | NCT04445389 |
|||
Kentucky Bioprocessing, Inc | Protein Subunit | RBD-based | 2 | 0, 21 days | IM | NCT04473690 |
|||
Sanofi Pasteur/GSK | Protein Subunit | S protein (baculovirus production) | 2 | 0, 21 days | IM | NCT04537208 |
|||
Biological E Ltd | Protein Subunit | Adjuvanted protein subunit (RBD) | 2 | 0, 28 days | IM | CTRI/2020/11/029032 |
|||
Israel Institute for Biological Research | Replicating Viral Vector | VSV-S | 1 | IM | NCT04608305 |
||||
Arcturus/Duke-NUS | RNA | mRNA | IM | NCT04480957 |
|||||
SpyBiotech/Serum Institute of India | VLP | RBD-HBsAg VLPs | 2 | 0, 28 days | IM | ACTRN12620000817943 |
|||
Symvivo | DNA | bacTRL-Spike | 1 | Oral | NCT04334980 |
||||
Providence Health & Services | DNA | electroporated S protein plasmid DNA vaccine with or without the combination of electroporated IL- 12p70 plasmid | 2 | 0, 28 days | ID | NCT04627675 |
|||
Codagenix/Serum Institute of India | Live Attenuated Virus | Codon deoptimized live attenuated vaccines | 1 or 2 | 0 or 0,28 days | IN | NCT04619628 |
|||
ImmunityBio, Inc. & NantKwest Inc. | Non-Replicating Viral Vector | hAd5 S+N 2nd Generation Human Adenovirus Type 5 Vector (hAd5) Spike (S) + Nucleocapsid (N) | 2 | 0, 21 days | SC | NCT04591717 |
|||
ReiThera/LEUKOCARE/Univercells | Non-Replicating Viral Vector | Replication defective Simian Adenovirus (GRAd) encoding S | 1 | IM | NCT04528641 | ||||
CanSino Biological Inc/Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China | Non-Replicating Viral Vector | Ad5-nCoV | 2 | 0, 28 days | IM/mucosal | NCT04552366 | |||
Vaxart | Non-Replicating Viral Vector | Ad5 adjuvanted Oral Vaccine platform | 2 | 0, 28 days | Oral | NCT04563702 | |||
Ludwig-Maximilians - University of Munich | Non-Replicating Viral Vector | MVA-SARS-2-S | 2 | 0, 28 days | IM | NCT04569383 | |||
City of Hope, USA | Replicating Viral Vector | SARS-CoV-2 S and NP genes inserted into a sMVA vector | 2 | 0, 28 days | IM | NCT04639466 | |||
Clover Biopharmaceuticals Inc./GSK/Dynavax | Protein Subunit | Native like Trimeric subunit Spike Protein vaccine | 2 | 0, 21 days | IM | NCT04405908 | |||
Vaxine Pty Ltd/Medytox | Protein Subunit | Recombinant spike protein with Advax™ adjuvant | 1 | IM | NCT04453852 | ||||
University of Queensland/CSL/Seqirus | Protein Subunit | Molecular clamp stabilized Spike protein with MF59 adjuvant | 2 | 0, 28 days | IM | ACTRN12620000674932p ISRCTN51232965 |
|||
Medigen Vaccine Biologics Corporation/NIAID/Dynavax | Protein Subunit | S-2P protein + CpG 1018 | 2 | 0, 28 days | IM | NCT04487210 | |||
Instituto Finlay de Vacunas, Cuba | Protein Subunit | rRBD produced in CHO-cell chemically conjugate to tetanus toxoid | 2 | 0, 28 days | IM | IFV/COR/06 | |||
Instituto Finlay de Vacunas, Cuba | Protein Subunit | RBD + Adjuvant | 2 | 0, 28 days | IM | IFV/COR/04 IFV/COR/05 |
|||
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo | Protein Subunit | Peptide | 2 | 0, 21 days | IM | NCT04527575 | |||
University Hospital Tuebingen | Protein Subunit | SARS-CoV-2 HLA-DR peptides | 1 | SC | NCT04546841 | ||||
COVAXX / United Biomedical Inc. Asia | Protein Subunit | Multitope peptide-based S1-RBD- protein vaccine | 2 | 0, 28 days | IM | NCT04545749 | |||
Chinese Academy of Military Sciences | Protein Subunit | Subunit expressed in CHO cells | 2 or 3 | 0, 14 days or 0,14, 28 days | IM | ||||
Merck Sharp & Dohme/IAVI | Replicating Viral Vector | Replication-competent VSV delivering the SARS-CoV-2 Spike | 1 | IM | NCT04569786 | ||||
Institute Pasteur/Themis/Univ. of Pittsburg CVR/Merck Sharp & Dohme | Replicating Viral Vector | Measles-vector based | 1 or 2 | 0, 28 days | IM | NCT04497298 | |||
Imperial College London | RNA | LNP-nCoVsaRNA | 2 | IM | ISRCTN17072692 | ||||
People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech. | RNA | mRNA | 2 | 0, 14 or 0, 28 days | IM | ChiCTR2000034112 ChiCTR2000039212 |
162 candidate vaccines in preclinical evaluation
Platform | Type of candidate vaccine | Developer | Coronavirus target |
Current stage of clinical evaluation/regulatory status- Coronavirus candidate |
Same platform for non-Coronavirus candidates | |||||||||||
DNA | DNA plasmids containing S-gene | Biosun Pharmed | SARS-CoV2 | Pre-Clinical | ||||||||||||
DNA | DNA plasmid vaccine | Globe Biotech Limited, Bangladesh | SARS-CoV2 | Pre-Clinical | ||||||||||||
DNA | Plasmid DNA, nanostructured RBD | National institute of Chemistry, Slovenia | SARS-CoV2 | Pre-Clinical | ||||||||||||
DNA |
DNA, engineered vaccine inserts compatible with multiple delivery systems |
DIOSynVax Ltd / University of Cambridge |
SARS-CoV-2 and Sarbeco-CoV |
Pre-Clinical | ||||||||||||
DNA | DNA vaccine | Ege University | SARS-CoV2 | Pre-Clinical | ||||||||||||
DNA | DNA plasmid vaccine RBD&N | Scancell/University of Nottingham/ Nottingham Trent University | SARS-CoV2 | Pre-Clinical | ||||||||||||
DNA | DNA plasmid vaccine S,S1,S2,RBD &N | National Research Centre, Egypt | SARS-CoV2 | Pre-Clinical | ||||||||||||
DNA | DNA with electroporation |
Karolinska Institute / Cobra Biologics (OPENCORONA Project) |
SARS-CoV2 | Pre-Clinical | ||||||||||||
DNA | DNA with electroporation | Chula Vaccine Research Center | SARS-CoV2 | Pre-Clinical | ||||||||||||
DNA | DNA | Takis/Applied DNA Sciences/Evvivax | SARS-CoV2 | Pre-Clinical | ||||||||||||
DNA | Plasmid DNA, Needle-Free Delivery | Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet | SARS-CoV2 | Pre-Clinical | SARS | |||||||||||
DNA | DNA vaccine | BioNet Asia | SARS-CoV2 | Pre-Clinical | ||||||||||||
DNA | msDNA vaccine | Mediphage Bioceuticals/University of Waterloo | SARS-CoV2 | Pre-Clinical | ||||||||||||
DNA | DNA vaccine | Entos Pharmaceuticals | SARS-CoV2 | Pre-Clinical | ||||||||||||
Inactivated | Inactivated + Alum | Shifa Pharmed | SARS-CoV2 | Pre-Clinical | ||||||||||||
Inactivated | Inactivated | Milad Pharmaceutics Co. | SARS-CoV2 | Pre-Clinical | MMR, IPV | |||||||||||
Inactivated | Inactivated | Zista Kian Azma Co. | SARS-CoV2 | Pre-Clinical | MMR, IPV | |||||||||||
Inactivated | Inactivated | Kocak Farma Ilac ve Kimya San. A.S. | SARS-CoV2 | Pre-Clinical | ||||||||||||
Inactivated |
Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018 |
Institute of Vaccines and Medical Biologicals (IVAC; Vietnam) / Dynavax / PATH |
SARS-CoV2 | Pre-Clinical | ||||||||||||
Inactivated |
Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018 |
Government Pharmaceutical Organization (GPO; Thailand) / Dynavax / PATH | SARS-CoV2 | Pre-Clinical | ||||||||||||
Inactivated |
Egg-based, inactivated, whole chimeric Newcastle Disease Virus (NDV) expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018 |
Institute Butantan (Brazil) / Dynavax / PATH | SARS-CoV-2 | Pre-clinical | ||||||||||||
Inactivated | Inactivated + alum | KM Biologics | SARS-CoV2 | Pre-Clinical | JE, Zika | |||||||||||
Inactivated | Inactivated | Selcuk University | SARS-CoV2 | Pre-Clinical | ||||||||||||
Inactivated | Inactivated | Erciyes University | SARS-CoV2 | Pre-Clinical | ||||||||||||
Inactivated | Inactivated whole virus | National Research Centre, Egypt | SARS-CoV2 | Pre-Clinical | ||||||||||||
Inactivated | Inactivated | SARS-CoV2 | Pre-Clinical | |||||||||||||
Inactivated | TBD | Osaka University/ BIKEN/ NIBIOHN | SARS-CoV2 | Pre-Clinical | ||||||||||||
Inactivated | Inactivated + CpG 1018 | Sinovac/Dynavax | SARS-CoV2 | Pre-Clinical | ||||||||||||
Inactivated | Inactivated + CpG 1018 | Valneva/Dynavax | SARS-CoV2 | Pre-Clinical | ||||||||||||
Live Attenuated Virus | Codon deoptimized live attenuated vaccines |
Mehmet Ali Aydinlar University / Acıbadem Labmed Health Services A.S. |
SARS-CoV2 | Pre-Clinical | ||||||||||||
Live Attenuated Virus | Codon deoptimized live attenuated vaccines | Indian Immunologicals Ltd/Griffith University | SARS-CoV2 | Pre-Clinical | ||||||||||||
Non Replicating Viral Vector | Ad 5 vector for intranasal administration | University of Helsinki & University of Eastern Finland | SARS-CoV2 | Pre-Clinical | ||||||||||||
Non Replicating Viral Vector | Adenovirus Type 5 Vector | Globe Biotech Limited, Bangladesh | SARS-CoV2 | Pre-Clinical | ||||||||||||
Non-Replicating Viral Vector | Sendai virus vector | ID Pharma | SARS-CoV2 | Pre-Clinical | ||||||||||||
Non-Replicating Viral Vector | Adenovirus-based | Ankara University | SARS-CoV2 | Pre-Clinical | ||||||||||||
Non-Replicating Viral Vector | Adeno-associated virus vector (AAVCOVID) | Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis | SARS-CoV2 | Pre-Clinical | ||||||||||||
Non-Replicating Viral Vector | MVA encoded VLP | GeoVax/BravoVax | SARS-CoV2 | Pre-Clinical | LASV, EBOV, MARV, HIV | |||||||||||
Non-replicating viral vector | MVA-S encoded | DZIF – German Center for Infection Research/IDT Biologika GmbH | SARS-CoV2 | Pre-clinical | Many | |||||||||||
Non-replicating viral vector | MVA-S | IDIBAPS-Hospital Clinic, Spain | SARS-CoV2 | Pre-clinical | ||||||||||||
Non-Replicating Viral Vector | Intranasal Ad5 vaccine encoding RBD | Altimmune, Inc. | SARS-CoV2 | IND filed |
Influenza (NasoVAX), Anthrax (NasoShield) |
|||||||||||
Non-Replicating Viral Vector | Adeno5-based | Erciyes University | SARS-CoV2 | Pre-Clinical | ||||||||||||
Non-Replicating Viral Vector | Ad5 S (GREVAX™ platform) | Greffex | SARS-CoV2 | Pre-Clinical | MERS | |||||||||||
Non-Replicating Viral Vector | Oral Ad5 S | Stabilitech Biopharma Ltd | SARS-CoV2 | Pre-Clinical | Zika, VZV, HSV-2 and Norovirus | |||||||||||
Non-Replicating Viral Vector | adenovirus-based + HLA-matched peptides | Valo Therapeutics Ltd | Pan-Corona | Pre-Clinical | ||||||||||||
Non-Replicating Viral Vector | Vaxart | SARS-CoV2 | Pre-Clinical | InfA, CHIKV, LASV, NORV; EBOV, RVF, HBV, VEE | ||||||||||||
Non-Replicating Viral Vector | MVA expressing structural proteins | Centro Nacional Biotecnología (CNB-CSIC), Spain | SARS-CoV2 | Pre-Clinical | Multiple candidates | |||||||||||
Non-Replicating Viral Vector |
parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein |
University of Georgia/University of Iowa | SARS-CoV2 | Pre-Clinical | MERS | |||||||||||
Non-Replicating Viral Vector |
Recombinant deactivated rabies virus containing S1 |
Bharat Biotech/Thomas Jefferson University | SARS-CoV2 | Pre-Clinical | HeV, NiV, EBOV, LASSA, CCHFV, MERS | |||||||||||
Non-Replicating Viral Vector | Influenza A H1N1 vector | National Research Centre, Egypt | SARS-CoV2 | Pre-Clinical | ||||||||||||
Non-Replicating Viral Vector | Newcastle disease virus expressing S | Icahn School of Medicine at Mount Sinai | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Recombinant spike with adjuvant | Iran | SARS-CoV2 | Pre-Clinical | Multiple candidates | |||||||||||
Protein Subunit | Recombinant S protein produced in BEVS | Tampere University | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit |
RBD protein delivered in mannose- conjugated chitosan nanoparticle |
Ohio State University / Kazakh National Agrarian University | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit |
Recombinant spike protein with Essai O/W 1849101 adjuvant |
Kazakh National Agrarian University | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Peptides | Neo7Logic | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit |
Recombinant spike protein with Essai O/W 1849101 adjuvant |
Kazakh National Agrarian University, Kazakhstan / National Scientific Center for Especially Dangerous Infections |
SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Recombinant S protein | Max-Planck-Institute of Colloids and Interfaces | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit |
RBD protein (baculovirus production) + FAR- Squalene adjuvant |
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH) |
SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Protein Subunit | Research Institute for Biological Safety Problems, Rep of Kazakhstan | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | RBD-protein | Mynvax | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Recombinant S protein | Izmir Biomedicine and Genome Center | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Peptide + novel adjuvant | Bogazici University | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit |
S subunit intranasal liposomal formulation with GLA/3M052 adjs. |
University of Virginia | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit |
S-Protein (Subunit) + Adjuvant, E coli based Expression |
Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria. |
SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Protein Subunit S,N,M&S1 protein | National Research Centre, Egypt | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Protein Subunit | University of San Martin and CONICET, Argentina | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | RBD protein fused with Fc of IgG + Adj. | Chulalongkorn University/GPO, Thailand | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Capsid-like Particle | AdaptVac (PREVENT-nCoV consortium) | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit |
Drosophila S2 insect cell expression system VLPs |
ExpreS2ion | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Peptide antigens formulated in LNP | IMV Inc | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | S protein | WRAIR/USAMRIID | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | S protein +Adjuvant | National Institute of Infectious Disease, Japan/Shionogi/UMN Pharma | SARS-CoV2 | Pre-Clinical | Influenza | |||||||||||
Protein Subunit | VLP-recombinant protein + Adjuvant |
Osaka University/ BIKEN/ National Institutes of Biomedical Innovation, Japan |
SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | microneedle arrays S1 subunit | Univ. of Pittsburgh | SARS-CoV2 | Pre-Clinical | MERS | |||||||||||
Protein Subunit | Peptide | Vaxil Bio | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Peptide | Flow Pharma Inc | SARS-CoV2 | Pre-Clinical |
Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, BreastCA vaccine |
|||||||||||
Protein Subunit | S protein | AJ Vaccines | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Ii-Key peptide | Generex/EpiVax | SARS-CoV2 | Pre-Clinical | Influenza, HIV, SARS-CoV | |||||||||||
Protein Subunit | S protein | EpiVax/Univ. of Georgia | SARS-CoV2 | Pre-Clinical | H7N9 | |||||||||||
Protein Subunit | Protein Subunit EPV-CoV-19 | EpiVax | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | gp-96 backbone | Heat Biologics/Univ. Of Miami | SARS-CoV2 | Pre-Clinical | NSCLC, HIV, malaria, Zika | |||||||||||
Protein Subunit | Subunit vaccine | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | S1 or RBD protein | Baylor College of Medicine | SARS-CoV2 | Pre-Clinical | SARS | |||||||||||
Protein Subunit | Subunit protein, plant produced | iBio/CC-Pharming | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit |
Recombinant protein, nanoparticles (based on S-protein and other epitopes) |
Saint-Petersburg scientific research institute of vaccines and serums | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit |
COVID-19 XWG-03 truncated S (spike) proteins |
Innovax/Xiamen Univ./GSK | SARS-CoV2 | Pre-Clinical | HPV | |||||||||||
Protein Subunit | Adjuvanted microsphere peptide | VIDO-InterVac, University of Saskatchewan | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit |
Synthetic Long Peptide Vaccine candidate for S and M proteins |
OncoGen | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit |
Oral E. coli-based protein expression system of S and N proteins |
MIGAL Galilee Research Institute | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Nanoparticle vaccine | LakePharma, Inc. | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit |
Plant-based subunit (RBD-Fc + Adjuvant) |
Baiya Phytopharm/ Chula Vaccine Research Center | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | OMV-based vaccine | Quadram Institute Biosciences | SARS-CoV2 | Pre-Clinical | Flu A, plague | |||||||||||
Protein Subunit | OMV-based vaccine | BiOMViS Srl/Univ. of Trento | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein subunit |
structurally modified spherical particles of the tobacco mosaic virus (TMV) |
Lomonosov Moscow State University | SARS-CoV2 | Pre-Clinical | rubella, rotavirus | |||||||||||
Protein Subunit | Spike-based | University of Alberta | SARS-CoV2 | Pre-Clinical | Hepatitis C | |||||||||||
Protein Subunit | Recombinant S1-Fc fusion protein | AnyGo Technology | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Recombinant protein | Yisheng Biopharma | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Recombinant S protein in IC-BEVS | Vabiotech | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Orally delivered, heat stable subunit | Applied Biotechnology Institute, Inc. | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Peptides derived from Spike protein | Axon Neuroscience SE | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Protein Subunit | MOGAM Institute for Biomedical Research, GC Pharma | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | RBD-based | Neovii/Tel Aviv University | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Outer Membrane Vesicle (OMV)-subunit | Intravacc/Epivax | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Outer Membrane Vesicle(OMV)-peptide | Intravacc/Epivax | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Spike-based (epitope screening) | ImmunoPrecise/LiteVax BV | SARS-CoV2 | Pre-Clinical | ||||||||||||
Protein Subunit | Spiked-based |
Nanografi Nano Technology, Middle East Technical University, Ankara University, |
SARS-CoV2 | Pre-Clinical | ||||||||||||
Replicating Bacteria Vector |
Oral Salmonella enteritidis (3934Vac) based protein expression system of RBD |
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH) |
SARS-CoV2 | Pre-Clinical | ||||||||||||
Replicating Viral Vector |
Intranasal Newcastle disease virus vector (rNDV-FARVET) expressing RBD |
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH) |
SARS-CoV2 | Pre-Clinical | ||||||||||||
Replicating Viral Vector | YF17D Vector | KU Leuven | SARS-CoV2 | Pre-Clinical | ||||||||||||
Replicating Viral Vector | Measles Vector | Cadila Healthcare Limited | SARS-CoV2 | Pre-Clinical | ||||||||||||
Replicating Viral Vector | Measles Vector | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo | SARS-CoV2 | Pre-Clinical | ||||||||||||
Replicating Viral Vector | Measles Virus (S, N targets) | DZIF – German Center for Infection Research/CanVirex AG | SARS-CoV2 | Pre-clinical | Zika, H7N9, CHIKV | |||||||||||
Replicating Viral Vector | Horsepox vector expressing S protein | Tonix Pharma/Southern Research | SARS-CoV2 | Pre-Clinical | Smallpox, monkeypox | |||||||||||
Replicating Viral Vector | Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal) | BiOCAD and IEM | SARS-CoV2 | Pre-Clinical | Influenza | |||||||||||
Replicating Viral Vector | Recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal) | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo | SARS-CoV2 | Pre-Clinical | Influenza | |||||||||||
Replicating Viral Vector |
Attenuated Influenza expressing an antigenic portion of the Spike protein |
Fundação Oswaldo Cruz and Instituto Buntantan | SARS-CoV2 | Pre-Clinical | Influenza | |||||||||||
Replicating Viral Vector | Influenza vector expressing RBD | University of Hong Kong | SARS-CoV2 | Pre-Clinical | ||||||||||||
Replicating Viral Vector | Replicating VSV vector-based DC-targeting | University of Manitoba | SARS-CoV2 | Pre-Clinical | ||||||||||||
Replicating Viral Vector | VSV-S | University of Western Ontario | SARS-CoV2 | Pre-Clinical | HIV, MERS | |||||||||||
Replicating Viral Vector | VSV-S | Aurobindo | SARS-CoV2 | Pre-Clinical | ||||||||||||
Replicating Viral Vector | VSV vector | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo | SARS-CoV2 | Pre-Clinical | ||||||||||||
Replicating Viral Vector |
M2-deficient single replication (M2SR) influenza vector |
UW–Madison/FluGen/Bharat Biotech | SARS-CoV2 | Pre-Clinical | influenza | |||||||||||
Replicating Viral Vector |
Newcastle disease virus vector (NDV-SARS- CoV-2/Spike) |
Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ. | SARS-CoV2 | Pre-Clinical | ||||||||||||
Replicating Viral Vector | Avian paramyxovirus vector (APMV) | The Lancaster University, UK | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | mRNA | Providence Therapeutics | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | mRNA | Cell Tech Pharmed | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | mRNA | ReNAP Co. | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | D614G variant LNP-encapsulated mRNA | Globe Biotech Ltd | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | saRNA formulated in a NLC | Infectious Disease Research Institute/ Amyris, Inc. | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | LNP-encapsulated mRNA encoding S | Max-Planck-Institute of Colloids and Interfaces | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | Self-amplifying RNA | Gennova | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | mRNA | Selcuk University | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | LNP-mRNA | Translate Bio/Sanofi Pasteur | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | LNP-mRNA | CanSino Biologics/Precision NanoSystems | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA |
LNP-encapsulated mRNA cocktail encoding VLP |
Fudan University/ Shanghai JiaoTong University/RNACure Biopharma | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | LNP-encapsulated mRNA encoding RBD | Fudan University/ Shanghai JiaoTong University/RNACure Biopharma | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA |
Replicating Defective SARS-CoV-2 derived RNAs |
Centro Nacional Biotecnología (CNB-CSIC), Spain | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | LNP-encapsulated mRNA | University of Tokyo/ Daiichi-Sankyo | SARS-CoV2 | Pre-Clinical | MERS | |||||||||||
RNA | Liposome-encapsulated mRNA | BIOCAD | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | Several mRNA candidates | RNAimmune, Inc. | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | mRNA | FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | mRNA | China CDC/Tongji University/Stermina | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | LNP-mRNA | Chula Vaccine Research Center/University of Pennsylvania | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | mRNA in an intranasal delivery system | eTheRNA | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | mRNA | Greenlight Biosciences | SARS-CoV2 | Pre-Clinical | ||||||||||||
RNA | mRNA | IDIBAPS-Hospital Clinic, Spain | SARS-CoV2 | Pre-Clinical | ||||||||||||
T-cell based |
CD8 T cell peptide targeting (S, M, N) and (NSPs) SARS-CoV-2 proteins |
OSE immunotherapeutics | SARS-CoV2 | Pre-Clinical | ||||||||||||
VLP | Plant derived VLP | Shiraz University | SARS-CoV2 | Pre-Clinical | ||||||||||||
VLP | VLPs produced in BEVS | Tampere University | SARS-CoV2 | Pre-Clinical | ||||||||||||
VLP | VLP | Max Planck Institute for Dynamics of Complex Technical Systems | SARS-CoV2 | Pre-Clinical | ||||||||||||
VLP |
Virus-like particle-based Dendritic Cell(DC)- targeting vaccine |
University of Manitoba | SARS-CoV2 | Pre-Clinical | ||||||||||||
VLP | VLP | Bezmialem Vakif University | SARS-CoV2 | Pre-Clinical | ||||||||||||
VLP | VLP | Middle East Technical University | SARS-CoV2 | Pre-Clinical | ||||||||||||
VLP | Enveloped Virus-Like Particle (eVLP) | VBI Vaccines Inc. |
SARS-CoV-2, SARS-CoV, MERS-CoV |
Pre-Clinical | CMV, GBM, Zika | |||||||||||
VLP | S protein integrated in HIV VLPs |
IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona Supercomputing Centre/Grifols |
SARS-CoV2 | Pre-Clinical | ||||||||||||
VLP | VLP + Adjuvant |
Mahidol University/ The Government Pharmaceutical Organization (GPO)/Siriraj Hospital |
SARS-CoV2 | Pre-Clinical | ||||||||||||
VLP |
Virus-like particles, lentivirus and baculovirus vehicles |
Navarrabiomed, Oncoimmunology group | SARS-CoV2 | Pre-Clinical | ||||||||||||
VLP |
Virus-like particle, based on RBD displayed on virus-like particles |
Saiba GmbH | SARS-CoV2 | Pre-Clinical | ||||||||||||
VLP | ADDomerTM multiepitope display | Imophoron Ltd and Bristol University’s Max Planck Centre | SARS-CoV2 | Pre-Clinical | ||||||||||||
VLP | Unknown | Doherty Institute | SARS-CoV2 | Pre-Clinical | ||||||||||||
VLP | VLP | OSIVAX |
SARS-CoV1 SARS-CoV2 |
Pre-Clinical | ||||||||||||
VLP | eVLP | ARTES Biotechnology | SARS-CoV2 | Pre-Clinical | malaria | |||||||||||
VLP | VLPs peptides/whole virus | Univ. of Sao Paulo | SARS-CoV2 | Pre-Clinical |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
